127 related articles for article (PubMed ID: 17952764)
41. A bispecific antibody to enhance radiotherapy by tumor necrosis factor-alpha in human CEA-expressing digestive tumors.
Azria D; Larbouret C; Garambois V; Gourgou S; Martineau P; Robert B; Dubois JB; Pelegrin A
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):580-8. PubMed ID: 14751531
[TBL] [Abstract][Full Text] [Related]
42. A combined therapy of hyperthermia and tumor necrosis factor for nude mice bearing KK-47 bladder cancer.
Amano T; Kumini K; Nakashima K; Uchibayashi T; Hisazumi H
J Urol; 1990 Aug; 144(2 Pt 1):370-4. PubMed ID: 2374209
[TBL] [Abstract][Full Text] [Related]
43. Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma.
Herman TS; Teicher BA
Cancer Res; 1988 May; 48(10):2693-7. PubMed ID: 3359430
[TBL] [Abstract][Full Text] [Related]
44. Enhancement of hyperthermia effect in vivo by amiloride and DIDS.
Lyons JC; Ross BD; Song CW
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(1):95-103. PubMed ID: 8416887
[TBL] [Abstract][Full Text] [Related]
45. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells.
Gnant MF; Turner EM; Alexander HR
Cytokine; 2000 Apr; 12(4):339-47. PubMed ID: 10805214
[TBL] [Abstract][Full Text] [Related]
46. Hyperthermic enhancement of tumor radiosensitization strategies.
Griffin RJ; Ogawa A; Williams BW; Song CW
Immunol Invest; 2005; 34(3):343-59. PubMed ID: 16136785
[TBL] [Abstract][Full Text] [Related]
47. Effect of thermochemotherapy (combined cyclophosphamide and hyperthermia) given at various temperatures with or without glucose administration on a murine fibrosarcoma.
Urano M; Kim MS; Kahn J; Kenton LA; Li ML
Cancer Res; 1985 Sep; 45(9):4162-6. PubMed ID: 4028008
[TBL] [Abstract][Full Text] [Related]
48. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice.
Kedar E; Palgi O; Golod G; Babai I; Barenholz Y
J Immunother; 1997 May; 20(3):180-93. PubMed ID: 9181456
[TBL] [Abstract][Full Text] [Related]
49. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
Griffin RJ; Williams BW; Park HJ; Song CW
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1516-22. PubMed ID: 15817358
[TBL] [Abstract][Full Text] [Related]
50. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor.
Farma JM; Puhlmann M; Soriano PA; Cox D; Paciotti GF; Tamarkin L; Alexander HR
Int J Cancer; 2007 Jun; 120(11):2474-80. PubMed ID: 17330231
[TBL] [Abstract][Full Text] [Related]
51. A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation.
Kleiter MM; Yu D; Mohammadian LA; Niehaus N; Spasojevic I; Sanders L; Viglianti BL; Yarmolenko PS; Hauck M; Petry NA; Wong TZ; Dewhirst MW; Thrall DE
Clin Cancer Res; 2006 Nov; 12(22):6800-7. PubMed ID: 17121901
[TBL] [Abstract][Full Text] [Related]
52. DNA damage produced by combined hyperglycemia and hyperthermia in two mouse fibrosarcoma tumors in vivo.
Murray D; Milas L; Meyn RE
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1679-82. PubMed ID: 6480453
[TBL] [Abstract][Full Text] [Related]
53. Enhancement of blood stasis and vascular permeability in Meth-A tumors by administration of hyperthermia in combination with tumor necrosis factor.
Umeno H; Watanabe N; Yamauchi N; Tsuji N; Okamoto T; Niitsu Y
Jpn J Cancer Res; 1994 Mar; 85(3):325-30. PubMed ID: 8188532
[TBL] [Abstract][Full Text] [Related]
54. Nanoparticle preconditioning for enhanced thermal therapies in cancer.
Shenoi MM; Shah NB; Griffin RJ; Vercellotti GM; Bischof JC
Nanomedicine (Lond); 2011 Apr; 6(3):545-63. PubMed ID: 21542691
[TBL] [Abstract][Full Text] [Related]
55. [Synergistic effects of human recombinant TNF and hyperthermia on in vitro cytotoxicity and artificial metastases].
Umeno H; Watanabe N; Sone H; Neda H; Yamauchi N; Maeda M; Niitsu Y; Urushizaki I
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1286-91. PubMed ID: 3579327
[TBL] [Abstract][Full Text] [Related]
56. In vivo response of murine RIF tumors to thermochemotherapy.
Neilan BA; Henle KJ
J Med; 1989; 20(1):107-12. PubMed ID: 2468731
[TBL] [Abstract][Full Text] [Related]
57. Combined treatment of IL-1 alpha and TNF-alpha potentiates the antitumour effect of hyperthermia.
Lin JC; Park HJ; Song CW
Int J Hyperthermia; 1996; 12(3):335-44. PubMed ID: 9044903
[TBL] [Abstract][Full Text] [Related]
58. Thermal combination therapies for local drug delivery by magnetic resonance-guided high-intensity focused ultrasound.
Hijnen N; Kneepkens E; de Smet M; Langereis S; Heijman E; Grüll H
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4802-E4811. PubMed ID: 28566498
[TBL] [Abstract][Full Text] [Related]
59. Step-down heating enhances the cytotoxicity of human tumour necrosis factor on murine and human tumour cell lines in vitro.
Klostergaard J; Akimaru Y; Tomasovic SP
Int J Hyperthermia; 1996; 12(1):97-114. PubMed ID: 8676012
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of changes in oxygen tension as indicators of RIF-1 tumor response to Nd:YAG laser heating.
Fahy AK; Waldow SM
Lasers Surg Med; 1993; 13(3):312-20. PubMed ID: 8515670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
